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Abstract
Purpose The COVID-19 infection is an aggressive viral illness with high risk of transmission during otolaryngology exami-
nation and surgery. Cholesteatoma is known for its potential to cause complications and scheduling of surgery during the 
pandemic must be done carefully. The majority of otological surgeries may be classified as elective and postponed at this 
time (e.g., stapedotomy, tympanoplasty); whereas, others are emergencies (e.g., complicated acute otitis media, complicated 
cholesteatoma with cerebral or Bezold’s abscess, meningitis, sinus thrombosis) and require immediate intervention. What 
is the ideal time for the surgical management of Cholesteatoma during the COVID-19 pandemic?
Methods Senior otologic surgeons from six teaching hospitals from various countries affected by the COVID-19 from around 
the world met remotely to make recommendations on reorganizing schedules for the treatment of cholesteatoma which has 
a risk of severe morbidity and mortality. The recommendations are based on their experiences and on available literature.
Results Due to the high risk of infecting the surgical staff it is prudent to stop all elective ear surgeries and plan cholesteatoma 
surgery after careful selection of patients, based on the extent of the disease and available resources. Specific precautions 
including use of appropriate personal protection equipment should be followed when operating on all patients during the 
pandemic. To facilitate the decision-making in the management of cholesteatoma, timing for surgery can be divided into 
two categories with 3 and 2 sub-groups based on disease severity.
Conclusions Evidence on the timing of surgery of patients with cholesteatoma during the COVID-19 pandemic is lacking. 
This manuscript contains practical tips on how cholesteatoma surgery can be reorganized during this pandemic.
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Introduction
The COVID-19 pandemic is an aggressive viral illness 
affecting most countries across the globe, with extensive 
person-to-person transmission, spread primarily via fomites 
and aerosols. In a patient infected with COVOD-19, the 
upper respiratory mucosa is found to have a high viral load, 
which increases the risk of transmission during otolaryngol-
ogy examination and surgery [1].
The annual incidence of cholesteatoma ranges from 
approximately 9 to 12.6 cases per 100,000 adults. In these 
patients, the disease may progress undiscovered until they 
have become large enough to erode the intra-temporal struc-
tures [2]. Kangsanarak et al. in a series of 24,321 patients 
recorded the incidence of intracranial complications at 
0.36% with a mortality of 18% among these patients. [3].
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Most surgeries for cholesteatoma are elective and can 
be postponed at this time; whereas, others are emergen-
cies (complicated cholesteatoma with cerebral or Bezold’s 
abscess, meningitis, sinus thrombosis, facial palsy) and 
require immediate intervention.
Now more than ever, it has become imperative that any 
decision-making regarding surgical management be driven 
by a risk–benefit assessment tailored to the individual 
patient. In some patients, surgery may be deferred and even 
follow-up visits postponed for a while. In others, the benefits 
of cholesteatoma surgery outweigh potential risk of COVID 
infection. Taking these points into consideration, we have 
drafted certain guidelines regarding surgical planning in 
those patients already diagnosed with cholesteatoma dur-
ing the COVID-19 pandemic.
Methods
Senior otologic surgeons from six teaching hospitals from 
various countries affected by the COVID-19 around the 
world met remotely to make recommendations on reorganiz-
ing schedules and safety protocols for the treatment of chole-
steatoma. The recommendations based on their experiences 
and on available literature were analyzed and summarized.
Discussion/observations
Effect of COVID‑19 pandemic on the elective 
management of cholesteatoma
At present, the diagnosis of COVID-19 is confirmed by the 
isolation of viral RNA from a nasal or throat swab [4, 5]. In 
the future, when the antibody testing of the virus becomes 
more widely available and approved for widespread clini-
cal use, the diagnosis of COVID-19 will hopefully become 
easier and accurate.
A more challenging scenario is to manage complicated 
cholesteatoma in a patient who has a COVID-19 infection. 
In most cases, it is advisable to put any otology surgery on 
hold if the infection is not life threatening or expected mor-
bidity is not significant. However, in some very specific and 
hopefully very rare situations where there is an emergency 
due to a complication of cholesteatoma, one might have to 
consider operating despite the COVID infection. This will 
undoubtedly complicate the perioperative course, pose diag-
nostic challenges and may potentially cause high mortality. 
It is, therefore, mandatory that any patient undergoing ear 
surgery be tested for COVID-19 preoperatively. Obviously, 
the treatment of cholesteatoma will also depend on the cur-
rent phase of the pandemic in each country with respect to 
the availability of personnel and hospital infrastructure that 
remains available to treat cholesteatoma at any given time.
Basic concepts in operating room safety 
during the COVID‑19 pandemic
Surgical treatment of cholesteatoma entails extensive drill-
ing (mastoidectomy), which is an aerosol-producing sur-
gery. As the virus is also likely to reside in the middle ear 
mucosa, surgery of a patient with an active viral infection 
poses an immense risk to the surgical team [6]. Appropri-
ate personal protection equipment (PPE) for this aerosol 
generating procedure is a N95 mask and face shield for all 
staff with surgery done in a theater with negative pressure 
atmosphere [7]. Enhanced PPE is ideal with a strong pref-
erence for use of powered air-purifying respirator (PAPR) 
[7–9]. The procedure must be done preferably by an expe-
rienced surgeon and the number of personnel inside the 
theater must be restricted. A full visor and PPE will hinder 
the use of a microscope and surgery may have to be done 
with an endoscope or an exoscope with image viewed on a 
screen if available. The surgeon can use a N95 mask with 
goggles in case the use of the microscope is needed, and the 
microscope offers some degree of protection to the surgeon. 
A high-speed drill is also to be avoided but in emergen-
cies may be done by reducing speed to decrease splashing 
or using curettes where possible as in a mastoid abscess. 
Any surgery in this situation without appropriate PPE will 
result in infections among the surgical team and is probably 
unwarranted. Availability of PPE is often a challenge even 
in the most well-equipped hospitals worldwide. Hence, we 
must consider the degree of urgency of the disease, the risk 
of the surgery, the risk of contamination of the healthcare 
team and the available resources (whether the hospital and 
resuscitation services are saturated or not) before scheduling 
a patient for surgery.
Grouping of patients with cholesteatoma 
and recommendations for optimal timing of surgery 
for patients during the COVID‑19 pandemic
Based on the recommendation by Saadi et al. [8], any oto-
logical procedure may be classified as elective (planned 
surgery within 6–12 months), semi-elective (surgery within 
3–6 months), semi-urgent (surgery within 48 h) and urgent 
(within 6–12 h). Under normal circumstances, most surger-
ies for uncomplicated cholesteatoma may be done as a semi-
elective procedure, i.e., with 3–6 months, or as an elective 
procedure (within 6–12 months), depending on a case-by-
case basis.
We aim to divide patients with cholesteatoma into cat-
egories A and B using the clinical and radiological data 
(Fig. 1) with various clinical groups in each category 
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(Table 1). This decision for the timing will be prioritized 
by the current COVID status of the patient and the avail-
ability of the operating room.
Category A: Patients with cholestatoma where surgery 
that can be deferred (has 3 clinical groups).
With increased availability of COVID-19 testing, the 
surgical planning may be done on a case-by-case basis. 
Here, the timing may be modified in COVID positives, as 
the primary disease is less dangerous than COVID-related 
complications. Rescheduling of patients who are COVID 
negative with uncomplicated cholesteatoma may help the 
capacity of the existing health care system to meet the 
existing needs. This is very much dependent on the phase 
of the pandemic. The characteristics of clinical groups in 
category A are:
1. Patients with inactive disease are those who have a dry 
ear with conductive hearing loss without significant 
bone erosion in high-resolution CT scan (HRCT) tem-
poral bone and could be planned for elective surgery.
2. Those have bone erosion in HRCT, but no risk for 
impending complications, will need surgery as semi-
elective. However, with the availability of COVID test-
ing and the individual hospital guidelines, the surgical 
planning may be changed on a case-by-case basis.
3. Patients with active disease but with no significant bone 
erosion (No vertigo, no facial palsy, no lateral canal 
fistula, no CSF leak) surgery can be planned as semi-
elective. In an active discharging ear, dry mopping or 
micro-suctioning (using a suction tip with no control 
hole) in the clinic can be performed till surgery.
Fig. 1  Categories of cholestea-
toma surgery during COVID-19 
pandemic
Categories of cholesteatoma surgery during COVID-19 Pandemic 
CATEGORY- A CATEGORY- B









Table 1  Clinical groups and recommendation of timing of surgery in patients with cholesteatoma during COVID-19 pandemic
Group Clinical findings/radiological (High-resolution CT temporal 
bone)
Timing of surgery in COVID phase
Category A
 1 Inactive disease (dry ear, conductive hearing loss, no significant 
bone erosion in the HRCT)
Elective
 2 Inactive disease (dry ear, significant bone erosion in the HRCT) Semi-elective (earlier surgery if progression of the disease with 
erosion of the tegmen/lateral canal erosion)
 3 Active disease, no significant bone erosion (no vertigo, no 
facial palsy, no lateral canal fistula, no CSF leak)
Semi-elective
Dry mopping/micro-suctioning in the clinic till surgery
Early surgery if disease progresses with erosion of tegmen/lateral 
canal
Category B
 1 Active disease, significant bone erosion (lateral canal fistula 
with vertigo and sensorineural loss [in only hearing ear], 
meningocele with CSF leak, facial paresis or facial palsy, 
mastoid abscess, petrositis)
Semi-urgent
 2 Active disease with life-threatening complications (meningitis, 
lateral sinus thrombosis, intracranial abscess)
Urgent
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Category B: Patients with cholesteatoma requiring surgery 
during the pandemic (has 2 clinical groups) irrespective of the 
current COVID status of the patient as the risk of the compli-
cations is far greater than the risk posed by the COVID-19 
infection. Patients must be duly counseled that prognosis of the 
surgical intervention is poorer if the patient is positive for the 
COVID-19 infection. Surgeons must also factor this in while 
making a risk–benefit assessment regarding treatment. The 
characteristics of clinical groups in category B are:
1. When patient presents with complications like facial 
palsy, lateral semicircular canal fistula and sensorineu-
ral hearing loss (in an only hearing ear), meningocele 
with CSF leak, mastoid abscess or petrositis, surgery 
will need to be performed as a semi-urgent procedure.
2. Patients with potential life-threatening complications 
like lateral sinus thrombosis or intracranial abscess will 
need urgent surgery. In patients who present with men-
ingitis, antibiotics should be started as early as possi-
ble. However, surgery may be deferred for 2–3 weeks 
if imaging shows no associated intracranial abscesses. 
Intracranial abscesses should be drained or treated medi-
cally in consultation with the neurosurgery team.
Special considerations
Certain cases with significant tegmen or sinus plate erosion or 
inactive disease with a lateral canal fistula on high-resolution 
CT scan, especially in an only hearing ear may require surgery 
within 6 weeks and it may be imprudent to wait for 3 months 
before undertaking surgery.
This proposal of grouping of cholesteatoma helps in the 
optimal timing for surgical intervention in all patients with or 
without COVID-19 infection, thus avoiding unnecessary anxi-
ety for the patient as well as for the surgeon. The indications 
for otological surgery under these circumstances must be kept 
as minimal as possible without compromising patient safety. 
However, the timing of surgical intervention may be changed 
based on the COVID status, and other hospital guidelines. In 
case of postponement of a surgical intervention which was 
planned before the pandemic, the reasons for postponement 
must be documented in a written report addressed to all the 
doctors participating in the patient’s care. It is important to 
inform the patient of the estimated time before surgery. In the 
meantime, the treating team should organize remote monitor-
ing or outpatient visits to assess the disease progression.
Conclusions
Cholesteatoma surgery during the COVID pandemic poses 
certain specific concerns. Owing to the significant risk of 
aerosol-mediated spread of the virus while drilling the 
mastoid, recommended safety precautions must be taken. 
The timing of surgery should take into consideration the 
severity of the disease, COVID status of the patient and the 
potential for complications associated with cholesteatoma 
if surgery is postponed. Therefore, the categorization of 
cholesteatoma into various sub-groups should help in the 
proper planning of surgery on a case-by-case basis, during 
the COVID-19 pandemic. These recommendations will also 
be useful if there are further recurrences of this disease or 
during similar pandemics in the future’.
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